WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018065993) A LDV LIPOSOMAL FORMULATION OF PHOTO SYSTEM-I FOR TREATMENT OF CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/065993    International Application No.:    PCT/IN2017/050405
Publication Date: 12.04.2018 International Filing Date: 16.09.2017
IPC:
A61K 9/127 (2006.01), A61K 47/69 (2017.01)
Applicants: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH [IN/IN]; Anusandhan Bhawan 2 Rafi Marg, New Delhi Delhi 110 001 (IN)
Inventors: GHOSH, Surajit; (IN).
SAHA, Abhijit; (IN).
GHOSH, Subhajit; (IN).
MOHAPATRA, Saswat; (IN).
JANA, Batakrishna; (IN).
BHUNIA, Debmalya; (IN)
Agent: REMFRY & SAGAR; Remfry House at The Millenium Plaza Sector 27, Gurgaon Haryana 122 009 (IN)
Priority Data:
201611034058 05.10.2016 IN
Title (EN) A LDV LIPOSOMAL FORMULATION OF PHOTO SYSTEM-I FOR TREATMENT OF CANCER
(FR) FORMULATION LIPOSOMALE DE LDV DE PHOTOSYSTÈME I POUR LE TRAITEMENT DU CANCER
Abstract: front page image
(EN)Present invention relates to a formulation from natural product. The formulation is LDV liposomal formulation of Photo System-I (PSI) which causes apoptotic death of cancer cells through ROS generation and a simple way for targeted delivery of the said formulation specifically to melanoma cancer cell. LDV liposomal formulation of PSI was prepared for targeted delivery to melanoma cancer cell. Through this targeted delivery inventors have shown that LDV liposomal formulation of PSI specifically kills melanoma cancer cells leaving normal cells unaffected. The present invention elucidates that LDV liposomal formulation of PSI is more potent anti-cancer agent than doxorubicin for melanoma.
(FR)La présente invention concerne une formulation à partir d'un produit naturel. La formulation est une formulation liposomale de LDV de Photosystème-I (PSI) qui provoque la mort apoptotique de cellules cancéreuses par génération de ROS et une manière simple pour une administration ciblée de ladite formulation spécifiquement à une cellule cancéreuse de mélanome. La formulation liposomale de LDV de PSI a été préparée pour une administration ciblée à une cellule cancéreuse de mélanome. Par cette administration ciblée, les inventeurs ont démontré que la formulation liposomale de LDV de PSI tue spécifiquement des cellules cancéreuses de mélanome laissant les cellules normales non affectées. La présente invention permet d'élucider que la formulation liposomale de LDV de PSI est un agent anti-cancer plus puissant que la doxorubicine pour le mélanome.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)